Pipeline Drug Substance 1
| Number | Product | CAS | Status | Indication | Manufacturing Process | Patent | |
|---|---|---|---|---|---|---|---|
| 1 | Oxerutin | R & D | Chronic Venous Insufficiency | Semi-synthesis | Expired |
|
|
| 2 | Conjugated Estrogens | 12126-59-9 | R & D | Estrogen Supplements | Total Synthesis | Expired |
|
| 3 | Polysulfated Glycosaminoglycan | R & D | Arthritis | Semi-synthesis | Expired |
|
|
| 4 | Berberine Hydrochloride | 633-65-8 | R & D | Anti-infection | Total Synthesis | Expired |
|
| 5 | Indigo Carmine | 860-22-0 | Pilot | Diagnostic Dye | Semi-synthesis | Expired |
|
Pipeline Drug Substance 2
| Number | Product | CAS | Target | Indication | First Launched Time/Country | Patent | |
|---|---|---|---|---|---|---|---|
| 1 | Resmetirom | 920509-32-6 | THR-β | Noncirrhotic Nonalcoholic Steatohepatitis | 2024-03 US | 2026-06 |
|
| 2 | Fezolinetant | 1629229-37-3 | NK-3R | Vasomotor Symptoms | 2023-05 US | 2034-03 |
|
| 3 | Etrasimod | 1206123-37-6 | S1PR | Ulcerative Colitis | 2023-10 US | 2030-03 |
|
| 4 | Darolutamide | 1297538-32-9 | AR | Non-metastatic Castration-Resistant Prostatic Cancer | 2019-07 US | 2030-10 |
|
| 5 | Venetoclax | 1257044-40-8 | Bcl-2 | Chronic Lymphocytic Leukemia | 2016-04 US | 2031-06 |
|
| 6 | Vorasidenib | 1644545-52-7 | IDH1/2 | Grade 2 Astrocytoma or Oligodendroglioma | 2024-08 US | 2034-07 |
|
| 7 | Sotagliflozin | 1018899-04-1 | SGLT-1/2 | Cardiovascular Death/Heart Failure | 2019-04 EU | 2028-05 |
|
| 8 | Orforglipron | 2212020-52-3 | GLP-1 | Weight Loss/Type 2 Diabetes | Phase 3 | 2037-09 |
|
| 9 | Deucravacitinib | 1609392-27-9 | TYK-2 | Plaque Psoriasis | 2022-09 US | 2033-11 |
|
| 10 | Ritlecitinib | 1792180-81-4 | JAK3/TEC | Alopecia Areata | 2023-06 US | 2034-12 |
|
